Asian Pacific journal of allergy and immunology最新文献

{"title":"Chronic cough management: Practical guidelines and PICO-based evidence for screening and investigation.","authors":"Dichapong Kanjanawasee, Orapan Poachanukoon, Thitiwat Sriprasart, Naricha Chirakalwasan, Narongkorn Saiphoklang, Athipat Athipongarporn, Anchalee Senavonge, Harutai Kamalaporn, Natthawan Sanguanwong, Wat Mitthamsiri, Chirawat Chiewchalermsri, Bandarn Suetrong, Aphichat Suwanchanratsamee, Pongsakorn Tantilipikorn, Monthira Maneerattanaporn, Pariyanan Jaruchinda, Theerasuk Kawamatawong, Varisara Luvira, Premsuda Sombuntham, Mongkhon Sompornrattanaphan, Triphoom Suwanwech, Nonpavit Chotchai, Kiat Ruxrungtham, Watchara Boonsawat, John Daniel Brannan, Woo-Jung Song, Prapaporn Pornsuriyasak","doi":"10.12932/AP-191124-1976","DOIUrl":"https://doi.org/10.12932/AP-191124-1976","url":null,"abstract":"<p><p>Chronic cough is a common clinical condition requiring comprehensive assessment. This review employs a symptom-focused approach, prioritizing the presenting symptom of \"chronic cough\" to mirror real-world clinical practice. Ten key questions regarding the investigations in the uncertain areas were systematically addressed based on the PICO framework and applying the GRADE system for evidence synthesis to provide the strength of recommendation and quality of evidence for key questions. Practical diagrams were developed to facilitate clinical decision-making. The initial evaluation involves screening for red flag signs requiring urgent attention, followed by a detailed history-taking and physical examination. A chest radiograph is recommended as the first-line investigation. The primary objective of the initial evaluation is to identify the cause and initiate appropriate treatment. If history and physical examination prove insufficient for a definitive diagnosis, referral to a specialist is advised for further specific testing. The recommendations on specific testing include fractional exhaled nitric oxide for cough variant asthma, nasal endoscopy or digital endoscopy (optional) for upper airway cough syndrome, paranasal sinus computed tomography (CT) for chronic rhinosinusitis, and laryngoscopy for hoarseness. Spirometry is for the diagnosis of obstructive airway diseases, and peak flow variability or bronchial challenge tests are complements particularly if asthma is suspected. Gastroesophageal reflux (GERD) investigations are for patients with chronic cough without typical GERD symptoms. Sinus radiographs and chest CT are not routinely recommended. Our guideline distinguishes itself by prioritizing a symptom-based clinical evaluation to guide clinicians toward the most probable diagnosis, streamlining the diagnostic process.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":"42 4","pages":"305-317"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Internalization of cell-derived microparticles triggers endothelial pro-inflammatory responses.","authors":"Phatchanat Klaihmon, Archrob Khuhapinant, Wasinee Kheansaard, Kovit Pattanapanyasat","doi":"10.12932/AP-040920-0952","DOIUrl":"10.12932/AP-040920-0952","url":null,"abstract":"<p><strong>Background: </strong>Increased numbers of circulating microparticles (MPs) have long been documented in thalassemia and are considered as a contributing factor in developing the thromboembolic events (TEEs), which are associated with endothelial dysfunction. Indeed, the cellular and molecular mechanisms by which MPs and endothelial cells interact and their consequences remain poorly investigated.</p><p><strong>Objective: </strong>The present study aims to compare the biological effects of MPs obtained from healthy subjects and β-thalassemia/HbE patients on endothelial pro-inflammatory responses.</p><p><strong>Methods: </strong>MPs isolated from plasma by two-step centrifugation from 10 healthy donors, 19 splenectomized and 30 non-splenectomized β-thalassemia/HbE patients were first characterized for their cellular origins, then counted and incubated with primary human umbilical vein endothelial cells (HUVECs). Internalization of MPs into HUVECs and their induction on endothelial cell activation and pro-inflammatory responses were determined.</p><p><strong>Results: </strong>MPs either from healthy or β-thalassemia/HbE patients could become internalized into endothelial cells, but unlike MPs from healthy donors and non-splenectomized patients, MPs from splenectomized patients were the most active and induced the 2-fold up-regulation of pro-inflammatory genes, IL1B, CXCL8, and CCL2 and 4-fold increase in interleukin-1β. In addition, MPs from both healthy subjects and splenectomized patients at 106/ml failed to trigger the secretion of endothelial IL-6 and IL-8 while higher MP concentration at 5 × 10⁶/ml significantly induced this secretion.</p><p><strong>Conclusions: </strong>Plasma MPs isolated from splenectomized β-thalassemia/HbE patients are capable of triggering pro-inflammatory responses from endothelial cells reflected at both gene and protein levels.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"420-428"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38882877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic cough management: Practical guidelines and PICO-based evidence for treatment.","authors":"Dichapong Kanjanawasee, Orapan Poachanukoon, Thitiwat Sriprasart, Naricha Chirakalwasan, Narongkorn Saiphoklang, Athipat Athipongarporn, Anchalee Senavonge, Harutai Kamalaporn, Natthawan Sanguanwong, Wat Mitthamsiri, Chirawat Chiewchalermsri, Bandarn Suetrong, Aphichat Suwanchanratsamee, Pongsakorn Tantilipikorn, Monthira Maneerattanaporn, Pariyanan Jaruchinda, Theerasuk Kawamatawong, Varisara Luvira, Premsuda Sombuntham, Mongkhon Sompornrattanaphan, Triphoom Suwanwech, Nonpavit Chotchai, Kiat Ruxrungtham, Watchara Boonsawat, John Daniel Brannan, Woo-Jung Song, Prapaporn Pornsuriyasak","doi":"10.12932/AP-191124-1974","DOIUrl":"https://doi.org/10.12932/AP-191124-1974","url":null,"abstract":"<p><p>This part reviews the management of chronic cough and proposes a management algorithm. Despite proven improvements in quality of life following chronic cough treatment, a clear understanding of the disease and the evidence for the efficacy of some treatments remain vague. Eight key questions regarding the treatment in the uncertain areas were systematically addressed based on the PICO framework and applying the GRADE system for evidence synthesis to provide the strength of recommendation and quality of evidence for key questions, with narrative components for the description of other chronic cough treatment including non-pharmacological therapy. Practical diagrams were developed to facilitate clinical decision-making on treatment. Our guideline introduces the concept of the cough management process for guiding practitioners to assess chronic cough using a holistic approach.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":"42 4","pages":"318-332"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication adherence, sensory attributes, and adverse effects of intranasal corticosteroids in allergic rhinitis patients: A systematic review and meta-analysis.","authors":"Baharudin Abdullah, Farah Dayana Zahedi, Aneeza Hamizan, Salina Husain","doi":"10.12932/AP-040424-1834","DOIUrl":"https://doi.org/10.12932/AP-040424-1834","url":null,"abstract":"<p><strong>Background: </strong>Intranasal corticosteroid (INCS) remains the primary treatment for allergic rhinitis (AR). Understanding adherence, safety concerns and sensory preferences is crucial for optimal care.</p><p><strong>Objective: </strong>This review aims to determine medication adherence, sensory attributes and adverse effects of INCS in AR patients.</p><p><strong>Methods: </strong>A systematic search of PubMed, Web of Science, Scopus, and Cochrane database was conducted for English articles published from 2004 to 2023. Eligibility includes clinical trials and observational studies with adult patients (18 years old or older) receiving INCS for AR (both intermittent and persistent).</p><p><strong>Results: </strong>Thirty-one studies with 10,582 patients, comprising 10 cross-sectional studies and 21 randomized controlled trials (RCT) were included. Adherence rates ranged from 28% to 87%, with an average of 55.8%. Forgetfulness was the primary reason for non-adherence (63.1-77.8%), followed by adverse events (26.4-61.5%) and fear of adverse events (3.8-31.5%). Scent (38%), taste (28.5%), or aftertaste (24.3%) were the main differentiators for sensory attribute, with varying levels of intensity and preferences for each INCS. Common adverse events encompass epistaxis, nasal dryness/irritation, headache and nasopharyngitis. A meta-analysis of eight RCT detected no significant difference in adverse events between the INCS and control groups (risk ratio 1.05; 95% confidence interval, 0.88-1.24; p = 0.61).</p><p><strong>Conclusions: </strong>The findings of this review indicate that medication adherence to INCS is not optimal, with non-adherence mostly attributed to forgetfulness, preferences for sensory attributes, and unpleasant effects associated with INCS. The underlying factors should be addressed as part of a multimodal strategy to improve adherence.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with poor asthma control in children: A prediction model.","authors":"Wanaporn Anuntaseree, Kanokpan Ruangnapa, Araya Yuenyongviwat, Kantara Saelim, Pharsai Prasertsan","doi":"10.12932/AP-170724-1894","DOIUrl":"https://doi.org/10.12932/AP-170724-1894","url":null,"abstract":"<p><strong>Background: </strong>Inhaled corticosteroids (ICS) are the first-line therapy for pediatric asthma. However, very few studies have developed simple tools for predicting treatment outcomes in pediatric asthma.</p><p><strong>Objective: </strong>This study aimed to construct a predictive model for poor asthma control in children after 6 months of ICS therapy.</p><p><strong>Methods: </strong>This retrospective study included children with asthma, aged 6-15 years, who received ICS with complete follow-up for 6 months. The potential factors associated with poor asthma control were also assessed. Poor control was considered if the child had partial or uncontrolled symptoms according to the Global Initiative for Asthma guidelines.</p><p><strong>Results: </strong>Among the 165 eligible children, 33 (20%) had poor symptom control. The factors associated with poor control were a history of more than four exacerbations in the 12 months before ICS treatment (odds ratio [OR], 3.39 [1.06, 10.83]), the presence of moderate to severe allergic rhinitis symptoms at the 6-month follow-up visit (OR, 21.93 [2.97, 162.05]), and poor adherence to asthma medications (OR, 4.16 [1.32, 13.12]). By incorporating these factors, a model for predicting poorly controlled asthma was constructed and converted into a nomogram with a total score of 200, with prediction risk ranging from 0 to 100%. The area under the receiver operating characteristic curve of the developed model was 0.737, indicating a moderate performance level.</p><p><strong>Conclusions: </strong>We developed a predictive tool for poor asthma control. The model has a good discriminatory ability and is simple to use, which could facilitate the individualized management of children with asthma.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic variations in Vitamin D Binding Protein (VDBP) impact vitamin D level and asthma susceptibility across the four ethnic populations.","authors":"Miao-Hsi Hsieh, Natalia Paramonova, Brigita Gradauskiene Sitkauskiene, Ilva Trapina, Ingrida Rumba-Rozenfelde, Sonomjamts Munkhbayarlakh, Samanta Plavina, Nikolajs Sjakste, Daina Bastyte, Laura Tamasauskiene, Ieva Stakaitiene, Rasa Ugenskiene, Pei-Chi Chen, Jiu-Yao Wang, Lawrence Shih-Hsin Wu","doi":"10.12932/AP-240324-1825","DOIUrl":"https://doi.org/10.12932/AP-240324-1825","url":null,"abstract":"<p><strong>Background: </strong>Asthma are associated with the vitamin D axis. Genetic variations of VDBP, notably rs7041 and rs4588, influence circulating vitamin D levels. However, data on their link to asthma are inconsistent, and ethnic differences remain unclear.</p><p><strong>Objective: </strong>We explored how genetic variations in VDBP affect vitamin D levels and susceptibility to asthma across diverse ethnic populations.</p><p><strong>Methods: </strong>In our cross-ethnic study, we analyzed vitamin D levels and VDBP polymorphisms (rs7041 and rs4588) in Taiwanese, Mongolian, Lithuanian, and Latvian populations. Our study included 363 asthmatic subjects and 481 non-asthma controls. We performed genotyping for rs7041 and rs4588 and assessed serum concentrations of 25-hydroxyvitamin D [25(OH)D], examining the associations between VDBP polymorphisms, vitamin D levels, and asthma.</p><p><strong>Results: </strong>The study found significant differences in vitamin D levels among ethnic groups. Non-asthmatic individuals from Taiwan had higher concentrations, while asthma subjects in both Taiwanese and Lithuanian populations showed lower levels compared to their non-asthma counterparts (both p-value < 0.001). VDBP polymorphisms were associated with asthma in the Latvian population, with the rs7041 GG vs. GT+TT showing an odds ratio (OR) of 1.72 (95% confidence interval (CI): 1.10-2.69, p = 0.016) and the rs4588 CC vs. CA+AA showing an OR of 1.88 (95%CI: 1.24-2.84, p = 0.003). However, this association was not observed in other populations.</p><p><strong>Conclusions: </strong>Our cross-ethnic study underscores the intricate relationship between VDBP genetic variations, vitamin D levels, and asthma vulnerability. The association of VDBP polymorphisms with asthma seems to differ among populations, emphasizing the importance of a nuanced comprehension of these connections.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Binding specificity of HuScFv to cholangiocarcinoma cells; New avenues for diagnosis and treatment.","authors":"Nathawadee Sawatpiboon, Monrat Chulanetra, Wanpen Chaicumpa, Sunisa Duang Sa-Ard, Kanda Kasetsinsombat, Adisak Wongkajornsilp","doi":"10.12932/AP-210624-1877","DOIUrl":"https://doi.org/10.12932/AP-210624-1877","url":null,"abstract":"<p><strong>Background: </strong>Cholangiocarcinoma (CCA) is a very aggressive cancer of the bile ducts. Recent advances in immunotherapy, particularly with human single-chain variable fragments (HuScFv), have shown promise in the treatment of solid tumors by targeting cancer cells or improving the immune response.</p><p><strong>Objective: </strong>This study aimed to select and produce human single-chain antibody fragments (HuScFv) specific to CCA cells (HubCCA1, RMCCA) from phage display HuScFv libraries with minimum or no binding to cholangiocytes (MMNK1).</p><p><strong>Methods: </strong>Phages that displayed HuScFv to CCA cells were selected by bio-panning and each phagemid was transduced to HB2151 E. coli. The presence of huscfv was determined by direct colony PCR. HuScFv was produced in the E. coli and detected by Western blot analysis and confirmed their specificity and binding capacity to CCA by flow cytometry.</p><p><strong>Results: </strong>From biopanning, 196 of 350 colonies (56%) of HB2151 E. coli harboring the huscfv gene, and 106 of these (30%) produced the protein. Flow cytometry testing with 14 clones confirmed the presence of the HuScFv protein. The result showed that five HuScFv clones (25, 33, 61, 68, and 80) exhibited stronger binding to CCA cell lines (HubCCA1, RMCCA) compared to cholangiocytes. Furthermore, each clone possessed a distinct amino acid sequence, suggesting unique binding specificities.</p><p><strong>Conclusions: </strong>HuScFv specific to CCA cells were successfully selected from phage display HuScFv libraries which offer new revenues to develop a pan-CCA immunotherapy and diagnosis of CCA.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chimeric peptides targeting the receptor-binding domain of SARS-CoV-2 variants inhibit ACE2 interaction.","authors":"Pisit Ubonsri, Jiraporn Panmanee, Ittipat Meewan, Promsin Masrinoul, Jukrapun Komaikul, Surapon Piboonpocanun","doi":"10.12932/AP-030424-1833","DOIUrl":"https://doi.org/10.12932/AP-030424-1833","url":null,"abstract":"<p><strong>Background: </strong>The receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein is pivotal in facilitating viral entry and serves as a major target for vaccine development and therapeutics. Despite undergoing mutations aimed at evading host immunity, certain regions within the RBD remain conserved.</p><p><strong>Objective: </strong>This study aimed to identify peptides capable of interacting with these conserved regions of the RBD across various variants and assess their neutralization potential.</p><p><strong>Methods: </strong>The PhD-12 phage display library underwent screening to identify phages binding to the RBD. Selected phage clones were examined for binding to the RBD of multiple variants, including 2019-nCoV, Delta (B.1.617.2), Omicron (B.1.1.529), and XBB. Peptides, expressed as chimeric constructs, were tested for their binding to the RBD, the Omicron trimeric S, inactivated SARS-CoV-2 virus, and neutralizing activity. The binding sites were analyzed using Molecular Docking.</p><p><strong>Results: </strong>Two selected phage clones displayed peptides binding to the RBD of multiple variants. Chimeric T hioredoxin-peptides (Trx-RB9 and Trx-RB10) exhibited binding to both inactivated SARS-CoV-2 and the Omicron trimeric S, with half-maximum effective concentrations (EC50 ) values of 111.9 and 360.2 nM, respectively. Molecular docking revealed distinct binding sites within the RBD of the Omicron trimeric S for both Trx-RB9 and Trx-RB10. A mixture of Trx-RB9 and Trx-RB10 inhibited 78% of the binding of recombinant human ACE2 to the Omicron trimeric S.</p><p><strong>Conclusions: </strong>The chimeric Trx-RB9 and Trx-RB10 peptides bind to the RBD of SARS-CoV-2 variants and inhibit the binding of ACE2 to the RBD of the Omicron trimeric S.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 10-year comparative study of factors for allergic asthma and/or rhinitis in two cross-sectional surveys.","authors":"Wanjun Wang, Jianhong Wang, Yan Jiang, Xiaoli Han, Guolin Tan, Jianjun Chen, Qianhui Qiu, Huabin Li, Jing Li","doi":"10.12932/AP-200424-1842","DOIUrl":"https://doi.org/10.12932/AP-200424-1842","url":null,"abstract":"<p><strong>Background: </strong>The allergenic relevance of the living environment changes over the last decades is largely unknown.</p><p><strong>Objective: </strong>We aimed to compare the factors associated with asthma and/or rhinitis between 2008 and 2018.</p><p><strong>Methods: </strong>We assessed two nationally representative cross-sectional datasets in 2008 and 2018. Within the rigorous protocol, questionnaire and serum IgE measurement were conducted in 2322 and 2353 patients with allergic asthma (A) and/or rhinitis (R) respectively. Multivariate logistic regression analysis was used to examine the effect of different factors on sensitization.</p><p><strong>Results: </strong>The prevalence of sensitization increased in rhinitis alone (A-R+, 63% in 2008 vs. 67.7% in 2018, P = 0.039) and asthma with rhinitis (A+R+, 70.6% vs. 75.1%, P = 0.014). The common factors for sensitization were male sex, using mattress and air conditioner, family history of rhinitis, building age > 30 years, and meat consumption. Compared with 2008, secondhand smoke was an additional risk factor for A+R- (odds ratio [OR] 2.17, 95% confidence interval [CI] 1.18-7.01) and A+R+ (OR 1.72, 95%CI 1.03-3.14), and the odds of farmland or forest for pollen and mold sensitization were higher in 2018 (OR 3.61, 95%CI 2.79-4.66, and OR 1.86, 95%CI 1.34-2.58). Eating fish was inversely associated with A-R+ (OR 0.68, 95%CI 0.52-0.91, P < 0.01), while older age also showed an inverse relationship with sensitization. The OR of age 25-44 years was higher in 2018.</p><p><strong>Conclusions: </strong>Repeated surveys showed variations in the factors affecting allergic asthma and/or rhinitis. The variable factors included age of 25-44 years, secondhand smoke, farmland, forest, and fish consumption.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Compound D from Zingiber cassumunar Roxb. attenuated type 2 inflammatory cytokine-induced tight junction disruption in airway epithelial cells.","authors":"Orapan Poachanukoon, Pasistha Termworasin, Phuntila Tharabenjasin, Thaweephol Dechatiwongse Na Ayudhya, Aekkacha Moonwiriyakit","doi":"10.12932/AP-180624-1873","DOIUrl":"https://doi.org/10.12932/AP-180624-1873","url":null,"abstract":"<p><strong>Background: </strong>Barrier disruption in the airway mucosae has been implicated in allergic type 2 inflammatory diseases such as allergic rhinitis and asthma. Zingiber cassumunar Roxb. has long been used in traditional medicine to treat allergic diseases. The active compound, namely compound D, has proven anti-inflammatory benefits. However, the effect of compound D on allergic inflammation remains unclear.</p><p><strong>Objective: </strong>This study aimed to investigate the protective effects of compound D on allergic inflammation-induced barrier disruption.</p><p><strong>Methods: </strong>Type 2 cytokine (IL-4 and IL-13)-exposed 16HBE human bronchial epithelial cells were treated with compound D. After 24, 48, and 72 h, cytotoxicity, epithelial integrity, and tight junction (TJ) disruption were determined by viability assays, transepithelial electrical resistance measurement, and immunofluorescence staining, respectively. Moreover, the mechanism of action of compound D was investigated by western blotting.</p><p><strong>Results: </strong>Compound D (100 and 200 µM) prevented IL-4/IL-13-induced barrier disruption at 24 and 48 h with no effect on cell viability. Compound D rescued the localization of ZO-1 to pericellular areas, and the barrier-protective effect of compound D was mediated by inhibiting STAT6 signaling.</p><p><strong>Conclusions: </strong>Compound D can suppress IL-4/IL-13-induced epithelial inflammation and TJ disruption through STAT6 inhibition. The agent is a promising candidate for therapeutic or adjunctive treatment of type 2 inflammation-associated diseases, including asthma.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}